PANRETIN
LOE Approachingalitretinoin
NDATOPICALGELPriority Review
Approved
Feb 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
12
Data completeness
4/8 — Partial
Priority Review
PANRETIN (alitretinoin) is (9-cis-retinoic acid) is a naturally occurring endogenous retinoid that binds to and activates all known intracellular retinoid receptor subtypes (rarα, rarβ, rarγ, rxrα, rxrβ and rxrγ). First approved in 1999.
Drug data last refreshed 52m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PANRETIN (alitretinoin) is a topical retinoid gel approved in 1999 for cutaneous manifestations of Kaposi's sarcoma. It works as a 9-cis-retinoic acid that activates all known intracellular retinoid receptors (RAR and RXR subtypes), functioning as a transcription factor to regulate cellular differentiation and proliferation in neoplastic cells. The drug directly inhibits KS cell growth in vitro through this receptor-mediated mechanism.
$0.965MPart D
LOE ApproachingDeclining
Minimal commercial infrastructure; product serves a niche indication with low claims volume and declining lifecycle stage.
Mechanism of Action
(9-cis-retinoic acid) is a naturally occurring endogenous retinoid that binds to and activates all known intracellular retinoid receptor subtypes (RARα, RARβ, RARγ, RXRα, RXRβ and RXRγ). Once activated these receptors function as transcription factors that regulate the expression of genes that…
Pharmacologic Class:
Retinoid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (12)
A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema
Started Jun 2022
513 enrolled
Chronic Hand Eczema
Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
Started Nov 2020
689 enrolled
Proliferative Diabetic Retinopathy
Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.
Started Apr 2014
94 enrolled
High Risk Proliferative Diabetic Retinopathy
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Started Mar 2012
305 enrolled
Proliferative Diabetic Retinopathy
Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus
Started Aug 2011
7 enrolled
Lupus Erythematosus, Cutaneous
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.